Pressured Intraperitoneal Aerosol Chemotherapy

Phase 2Small molecule

Pressured Intraperitoneal Aerosol Chemotherapy is one of 3 small molecule programs targeting Intraperitoneal. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IntraperitonealRecruiting

IntraperitonealPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Intraperitoneal

#DrugCompanyPhaseTrials

Bupivacain

IIstanbul University

Phase 1

1 2

Pressured Intraperitoneal Aerosol Chemotherapy

TThe University of Hong Kong

Phase 2

1 3

Etanidazole

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Intraperitoneal

NCT06367270

Clinical

Trials by Indication[1]

Intraperitoneal1 trial

The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies

Recruiting·TThe University of Hong Kong·Phase 2·NCT06367270·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pressured Intraperitoneal Aerosol Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pressured Intraperitoneal Aerosol Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pressured Intraperitoneal Aerosol Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Hong Kong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe University of Hong Kong

Pressured Intraperitoneal Aerosol Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Intraperitoneal1 trial

References

Drug Info

Quick Facts

Related News